What is Singular Research’s Forecast for QNTM Q1 Earnings?

Quantum Biopharma Ltd. (NASDAQ:QNTM) – Research analysts at Singular Research issued their Q1 2026 earnings per share estimates for Quantum Biopharma in a note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan forecasts that the company will post earnings of ($0.07) per share for the quarter. Singular Research currently has a “Moderate Buy” rating on the stock. The consensus estimate for Quantum Biopharma’s current full-year earnings is ($3.27) per share. Singular Research also issued estimates for Quantum Biopharma’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.53) EPS.

Quantum Biopharma (NASDAQ:QNTM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.04). The firm had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $2.09 million.

Separately, Wall Street Zen raised Quantum Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th.

Quantum Biopharma Stock Performance

NASDAQ QNTM opened at $27.13 on Monday. Quantum Biopharma has a 52-week low of $2.70 and a 52-week high of $38.25. The company has a fifty day moving average of $12.54 and a 200-day moving average of $7.97. The company has a market capitalization of $78.95 million, a P/E ratio of -1.70 and a beta of 0.55.

Institutional Trading of Quantum Biopharma

An institutional investor recently raised its position in Quantum Biopharma stock. AdvisorShares Investments LLC grew its holdings in Quantum Biopharma Ltd. (NASDAQ:QNTM) by 163.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 69,078 shares of the company’s stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent quarter. 1.24% of the stock is currently owned by institutional investors and hedge funds.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.